Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527904 · ClinicalTrials.gov registry record · Phase 3
A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)
A Phase 3 study, sponsored by POZEN.
- Completed
- Registry status
- Phase 3
- Development phase
- 239
- Enrollment target
NCT00527904 is a Phase 3 study that has completed, run by POZEN. The registered enrollment target is 239 participants.
The verdict
NCT00527904, a Phase 3 study, has completed, sponsored by POZEN.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 239 participants
- Enrollment target
Study Summary
This study uses an open-label design and will be conducted in approximately 60 sites aiming to enroll a total number of 200 subjects to ensure that at least 100 subjects will have 12 months exposure to PN400 (VIMOVO).
Interventions
- DRUG PN 400 (VIMOVO)
- DRUG PN400 (VIMOVO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00527904
The ClinicalTrials.gov registry entry for NCT00527904 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POZEN, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PN 400 (VIMOVO) is the first listed.
NCT00527904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00527904 about?
NCT00527904 is a clinical study titled "A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)". This study uses an open-label design and will be conducted in approximately 60 sites aiming to enroll a total number of 200 subjects to ensure that at least 100 subjects will have 12 months exposure to PN400 (VIMOVO).
What is the current status of trial NCT00527904?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 239 participants. The study started on 2007-03. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00527904?
The interventions under investigation include: PN 400 (VIMOVO) (DRUG), PN400 (VIMOVO) (DRUG).
Who is sponsoring clinical trial NCT00527904?
This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.